A new generation of mesenchymal stromal/stem cells differentially trained by immunoregulatory probiotics in a lupus microenvironment

• Published in: Stem cell research & therapy 2023-12, Vol.14 (1), p.358-358, Article 358
• Main Authors: Hoseinzadeh, Akram, Mahmoudi, Mahmoud, Rafatpanah, Houshang, Rezaieyazdi, Zahra, Tavakol Afshari, Jalil, Hosseini, Sara, Esmaeili, Seyed-Alireza
• Format: Article
• Language: English
• Subjects: Analysis; Anti-DNA antibodies; Antibodies; Autoimmune diseases; Bacteria; Bone marrow; Cancer; Creatinine; Cytokines; Disease; Enzyme-linked immunosorbent assay; Enzymes; Flow cytometry; Immune system; Immunomodulation; Immunoregulation; Inflammation; Inflammatory diseases; Interleukin 17; Kidney diseases; Lactobacillus; Lupus; Lupus nephritis; Medical research; Medical treatment; Medicine, Experimental; Mesenchymal stem/stromal cells; Microbiota; Microenvironments; Microorganisms; Phenotypes; Pristane; Probiotics; Proteinuria; Serum levels; Splenocytes; Stem cell transplantation; Stem cells; Stromal cells; Systemic lupus erythematosus; T cells; Transforming growth factor-b; Transforming growth factors; Viral antibodies
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-023-03578-z

Increasing evidence suggests that multipotent mesenchymal stem/stromal cells (MSCs) are a promising intervention strategy in treating autoimmune inflammatory diseases. It should be stated that systemic immunoregulation is increasingly recognized among the beneficial effects of MSCs and probiotics in treating morbid autoimmune disorders such as lupus. This study aimed to determine if immunoregulatory probiotics L. rhamnosus or L. delbrueckii can change the immunomodulatory effects of MSCs in lupus-like disease. Pristane-induced lupus (PIL) mice model was created via intraperitoneal injection of Pristane and then confirmed. Naïve MSCs (N-MSCs) were coincubated with two Lactobacillus strains, rhamnosus (R-MSCs) or delbrueckii (D-MSCs), and/or a combination of both (DR-MSCs) for 48 h, then administrated intravenously in separate groups. Negative (PBS-treated normal mice) and positive control groups (PBS-treated lupus mice) were also investigated. At the end of the study, flow cytometry and enzyme-linked immunosorbent assay (ELISA) analysis were used to determine the percentage of Th cell subpopulations in splenocytes and the level of their master cytokines in sera, respectively. Moreover, lupus nephritis was investigated and compared. Analysis of variance (ANOVA) was used for multiple comparisons. Abnormalities in serum levels of anti-dsDNA antibodies, creatinine, and urine proteinuria were significantly suppressed by MSCs transplantation, whereas engrafted MSCs coincubation with both L. strains did a lesser effect on anti-dsDNA antibodies. L. rhamnosus significantly escalated the ability of MSCs to scale down the inflammatory cytokines (IFN-ɣ, IL-17), while L. delbrueckii significantly elevated the capacity of MSCs to scale down the percentage of Th cell subpopulations. However, incubation with both strains induced MSCs with augmented capacity in introducing inflammatory cytokines (IFN-ɣ, IL-17). Strikingly, R-MSCs directly restored the serum level of TGF-β more effectively and showed more significant improvement in disease parameters than N-MSCs. These results suggest that R-MSCs significantly attenuate lupus disease by further skew the immune phenotype of MSCs toward increased immunoregulation. Results demonstrated that Lactobacillus strains showed different capabilities in training/inducing new abilities in MSCs, in such a way that pretreated MSCs with L. rhamnosus might benefit the treatment of lupus-like symptoms, given their desirable properties.